Research Highlight | Published:

DRUG THERAPY

ARAMIS — is darolutamide set to become the ‘third musketeer’ of nmCRPC?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

    Original article

    1. Fizazi, K. et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1815671 (2019)

    Download references

    Author information

    Correspondence to David Killock.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark